Sign In
Buy BLUE
$4.97
+0 (+0%)
At Close: Aug 29, 2025
FDA Committee Endorses bluebird's (BLUE) Thalassemia Therapy
03:03pm, Monday, 13'th Jun 2022
An FDA advisory committee favors approval for bluebird bio's (BLUE) beti-cel to treat transfusion-dependent thalassemia. A final decision by the regulatory body is expected on Aug 19, 2022.
Bluebird (BLUE) Stock Soars 25% Following 2 FDA Recommendations
10:57am, Monday, 13'th Jun 2022
Bluebird Bio (BLUE) stock is gaining on Monday following positive news last week from an advisory committee set up by the FDA. The post Bluebird (BLUE) Stock Soars 25% Following 2 FDA Recommendations
Bluebird's stock is up 70% after FDA committee voted in favor of the company's gene therapies last week
08:20am, Monday, 13'th Jun 2022
Shares of Bluebird Bio Inc. BLUE, +3.32% soared 71.8% in premarket trading on Monday, days after a Food and Drug Administration advisory committee voted in favor of two of the company's experimental g
FDA Advisory Committee Backs Bluebird Bio's Blood Disorder Gene Therapy
06:50am, Monday, 13'th Jun 2022
The FDA's Advisory Committee has unanimously backed Bluebird bio Inc's (NASDAQ: BLUE) gene therapy for a rare blood disorder. The panel of 13 voted unanimously for betibeglogene autotemcel (beti-ce
Bluebird Bio stock rises 62%, FDA committee supports treatments
09:40pm, Friday, 10'th Jun 2022 MarketWatch
Shares of Bluebird Bio Inc. rally more than 60% after news that a U.S. FDA committee supports two of the company's gene therapies.
FDA Committee Recommends bluebird's (BLUE) CALD Therapy
07:30pm, Friday, 10'th Jun 2022 Zacks Investment Research
An FDA advisory committee supports approving bluebird bio's (BLUE) eli-cel for treating cerebral adrenoleukodystrophy. NASDAQ halts trading BLUE's common stock on Jun 9 and 10.
An FDA Approval Could Send This Stock Soaring by August
05:03pm, Friday, 10'th Jun 2022 The Motley Fool
Two new treatments are under review, and one of them just might be a game-changer.
FDA Committee Recommends bluebird's (BLUE) CALD Therapy
04:33pm, Friday, 10'th Jun 2022
An FDA advisory committee supports approving bluebird bio's (BLUE) eli-cel for treating cerebral adrenoleukodystrophy. NASDAQ halts trading BLUE's common stock on Jun 9 and 10.
An FDA Approval Could Send This Stock Soaring by August
01:03pm, Friday, 10'th Jun 2022
Two new treatments are under review, and one of them just might be a game-changer.
bluebird (BLUE) Up as FDA Nod Likely for Thalassemia Therapy
05:21pm, Wednesday, 08'th Jun 2022 Zacks Investment Research
Based on briefing documents issued by the FDA, a positive regulatory approval is expected on bluebird bio's (BLUE) gene-therapy for treating thalassemia.
bluebird (BLUE) Up as FDA Nod Likely for Thalassemia Therapy
03:48pm, Wednesday, 08'th Jun 2022
Based on briefing documents issued by the FDA, a positive regulatory approval is expected on bluebird bio's (BLUE) gene-therapy for treating thalassemia.
Bluebird (BLUE) Down 6.2% Since Last Earnings Report: Can It Rebound?
03:30pm, Wednesday, 08'th Jun 2022 Zacks Investment Research
Bluebird (BLUE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Bluebird (BLUE) Down 6.2% Since Last Earnings Report: Can It Rebound?
12:48pm, Wednesday, 08'th Jun 2022
Bluebird (BLUE) reported earnings 30 days ago. What's next for the stock?
FDA Sounds Positive On Bluebird's One Gene Therapy But Doubts Another
01:47pm, Tuesday, 07'th Jun 2022
The FDA signaled in briefing documents released that it may approve Bluebird bio Inc's (NASDAQ: BLUE) beti-cel gene therapy to treat β-thalassemia for those who require regular blood transfusion
6 Biotech Stocks to Buy Now Ahead of These June Catalysts
05:11pm, Friday, 03'rd Jun 2022
Biotech investors stand to make a windfall if they make calculated bets by thoroughly researching on key catalysts that could move the stocks in a big way. The post 6 Biotech Stocks to Buy Now Ahead o
